Genomtec has signed an exclusive distribution agreement in Greece for its flagship Genomtec®ID genetic testing platform and the Respiratory Panel 5-plex test. Genomtec’s commercial partner Atropos Ltd., is a specialist distributor of molecular biology solutions with an established market position in Greece. Atropos will start the distribution following the regulatory approval of the Genomtec®ID platform and the test. Atropos has committed to a minimum order for both the analyzer and reaction cards for the rapid diagnosis of respiratory infections with a total value of €350,000 over a 3-year period. Genomtec plans to register the Genomtec®ID in the middle of this year.
– This is exciting news for us, our investors, patients and healthcare managers. We are in the process of clinical trials with the use of our Genomtec®ID platform, which we intend to register in the European Union in the middle of this year. This distribution agreement confirms that our idea, which our entire team has been working hard on for almost six years, has attracted market interest and is poised to empower physicians with technology that can improve patient outcomes. With Genomtec®ID we will augment the genetic laboratory to doctor’s offices, hospital emergency rooms or ambulances and the speed of test results obtained in this way will give patients a chance for a quick and precise diagnosis during a single meeting – said Charudutt Shah, Chief Business Officer in Genomtec.
ATROPOS Ltd, has been present on the market of in-vitro diagnostics and food quality control for 30 years and considers public health and consumer safety as its most important values. Thanks to its success, Atropos has established itself as a reliable provider of high-quality, innovative diagnostic solutions and financial stability.
The first disease panel that Genomtec®ID will detect is a respiratory panel, which continues to be an important need in the current period with continuation of COVID-19 disease. The panel will test for infection with one of five pathogens in a single test including: SARS-Cov-2, Influenza A/B, Respiratory Syncytial Virus (RSV), Mycoplasma pneumoniae and Chlamydophila pneumoniae.